Bioxtreme has secured a total of US$15m in funding to strengthen its leadership team and support the development of its rehab robotics.
NR Times speaks to CEO Eyal Samuel Shachar about the company’s plans for the funding and finds out more about Bioxtreme’s innovative Error Augmentation technology, which offers a unique new approach to neuro-rehab.
What does this new investment mean for the company?
The strategic investment, led by Serra Holding, brings Bioxtreme’s total funding to US$15 million and marks a pivotal step in the company’s growth.
It enables expanded operations across the United States and Europe, strengthens leadership and scientific collaboration and will accelerate the further development of next-generation neurorehabilitation technologies.
Tell us about Plaxtreme and why is it significant?
Plaxtreme is Bioxtreme’s advanced robotic rehabilitation device designed to restore functional hand movement.
It combines precision robotics, immersive virtual environments, and proprietary error augmentation technology to accelerate motor recovery.
Its focus on grasp and release functions addresses an important need in neurorehabilitation, particularly for stroke survivors.
What makes Plaxtreme especially significant is its ability to translate innovation into measurable outcomes.
In clinical studies, we’ve demonstrated significant improvements in functional tasks within a relatively short time frame, including gains in grasp, grip, and pinch strength.
These are not just isolated metrics, but meaningful capabilities that directly impact a patient’s ability to perform everyday activities.
By combining advanced technology with clinically validated results, Plaxtreme represents a step forward in delivering faster, more effective, and functionally relevant recovery.
How does Bioxtreme’s error augmentation technology work?
Bioxtreme’s Error Augmentation technology works by amplifying a patient’s movement errors in a precise and controlled way, triggering the brain’s natural adaptive responses.
Instead of minimising mistakes, the system strategically enhances them to encourage the brain to recognise, correct, and learn more effectively.
This approach strengthens Neuroplasticity, the brain’s lifelong ability to reorganise its functions and neural connections, helping patients relearn movements faster and improve overall motor accuracy.
What makes this especially powerful is the integration of real-time machine learning (AI).
The system continuously analyses each patient’s performance by tracking movement patterns, force generation, timing, and accuracy, and builds a personalised model of their abilities.
Based on this, adaptive algorithms dynamically adjust the level and type of error augmentation during therapy.
If a patient improves, the system increases the challenge; if they struggle, it fine-tunes the assistance or error signal to keep them in an optimal learning zone.
Why was now the right time to expand Bioxtreme’s leadership team?
As Bioxtreme enters this new phase of growth driven by this investment and our product innovation, it has never been more important to have leadership in place that knows how to scale operations and deepen clinical partnerships while helping us grow.
These additions to the leadership team ensure the company is positioned to execute effectively across both the U.S. and European markets.
How will the new leadership team support adoption in the U.S. and European markets?
Bioxtreme’s new leadership team brings proven experience in scaling and penetrating global markets with advanced medical and robotics products, navigating complex healthcare systems, reimbursement environments, and distributor networks.
Equally important, the team combines strong go-to-market expertise with deep product thinking.
They understand how to position innovative technologies like Error Augmentation in a way that resonates with clinicians, administrators, and patients.
What role does the Scientific Advisory Board play in Bioxtreme’s growth?
The Scientific Advisory Board plays a critical role in ensuring that Bioxtreme grows on a foundation of both clinical relevance and cutting-edge technology.
With leaders like Dr. Franco Molteni, who brings deep hands-on clinical experience, we stay closely aligned with real patient needs, clinical workflows, and outcome-driven therapy design.
At the same time, experts like Dr. Jim Patton bring world-class engineering expertise, especially in robotic systems and Error Augmentation, helping us push the boundaries of what’s possible in neurorehabilitation.
Together, the board ensures that our innovation sits at the intersection of science, engineering, and clinical impact—guiding product development, validating our approach, and strengthening our credibility with clinicians, researchers, and partners worldwide.
What’s next for Bioxtreme?
Bioxtreme is focused on scaling globally, advancing its product portfolio, and deepening clinical partnerships across the United States and Europe.
With new investment and expanded leadership in place, the company is accelerating commercialisation efforts for Plaxtreme and continued development of Dextreme, while strengthening our collaborations with clinicians and rehabilitation centers to support adoption of our breakthrough technology.
Learn more about Bioxtreme at bioxtremerobotics.com
3D-printed brain sensors could unlock personalised neural monitoring
